全文获取类型
收费全文 | 27971篇 |
免费 | 2886篇 |
国内免费 | 692篇 |
专业分类
耳鼻咽喉 | 107篇 |
儿科学 | 440篇 |
妇产科学 | 410篇 |
基础医学 | 3041篇 |
口腔科学 | 1011篇 |
临床医学 | 3289篇 |
内科学 | 4022篇 |
皮肤病学 | 317篇 |
神经病学 | 3864篇 |
特种医学 | 749篇 |
外国民族医学 | 4篇 |
外科学 | 1473篇 |
综合类 | 3309篇 |
现状与发展 | 2篇 |
预防医学 | 3967篇 |
眼科学 | 328篇 |
药学 | 2850篇 |
11篇 | |
中国医学 | 695篇 |
肿瘤学 | 1660篇 |
出版年
2024年 | 41篇 |
2023年 | 411篇 |
2022年 | 501篇 |
2021年 | 1141篇 |
2020年 | 1030篇 |
2019年 | 1090篇 |
2018年 | 993篇 |
2017年 | 1120篇 |
2016年 | 1281篇 |
2015年 | 1358篇 |
2014年 | 1816篇 |
2013年 | 2413篇 |
2012年 | 1740篇 |
2011年 | 1807篇 |
2010年 | 1395篇 |
2009年 | 1289篇 |
2008年 | 1200篇 |
2007年 | 1313篇 |
2006年 | 1096篇 |
2005年 | 1004篇 |
2004年 | 899篇 |
2003年 | 833篇 |
2002年 | 649篇 |
2001年 | 619篇 |
2000年 | 498篇 |
1999年 | 410篇 |
1998年 | 394篇 |
1997年 | 358篇 |
1996年 | 339篇 |
1995年 | 333篇 |
1994年 | 252篇 |
1993年 | 237篇 |
1992年 | 205篇 |
1991年 | 159篇 |
1990年 | 162篇 |
1989年 | 128篇 |
1988年 | 105篇 |
1987年 | 110篇 |
1986年 | 90篇 |
1985年 | 117篇 |
1984年 | 121篇 |
1983年 | 86篇 |
1982年 | 89篇 |
1981年 | 84篇 |
1980年 | 75篇 |
1979年 | 48篇 |
1978年 | 26篇 |
1977年 | 22篇 |
1976年 | 26篇 |
1975年 | 11篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的 了解铜陵市人民医院2017年临床分离细菌对抗菌药物的耐药状况。方法 对2017年1-12月临床分离菌采用纸片扩散法(KB)进行药敏试验,按CLSI 2017年版标准判读药敏试验结果,采用WHONET 5.6软件进行数据分析。结果 临床分离细菌共3436株,其中革兰阳性菌719株,占20.9%;革兰阴性菌2717株,占79.1%。耐甲氧西林金黄色葡萄球菌(MRSA)和耐甲氧西林凝固酶阴性葡萄球菌(MRCNS)的检出率分别为23.8%和72.3%,耐甲氧西林株对β-内酰胺类抗生素和其他测试抗菌药物的耐药率显著高于甲氧西林敏感株,未发现对万古霉素和替考拉宁耐药的葡萄球菌。粪肠球菌对青霉素、氨苄西林和呋喃妥因的耐药率较低,屎肠球菌对氯霉素的耐药率较低,5.3%屎肠球菌对万古霉素耐药。大肠埃希菌、克雷伯菌属(肺炎克雷伯菌和产酸克雷伯菌)和奇异变形菌中ESBLs的检出率分别为41.4%、50.7%和19.4%。肠杆菌科细菌中克雷伯菌属和沙雷菌属对碳青霉烯类抗生素耐药率较高,分别为37.5%和36.0%,其他菌属的耐药率低于3%。鲍曼不动杆菌对亚胺培南和美罗培南的耐药率分别80.3%和79.1%;铜绿假单胞菌对亚胺培南和美罗培南的耐药率分别为29.7%和28.4%。肺炎克雷伯菌、鲍曼不动杆菌和铜绿假单胞菌中广泛耐药株的检出率分别为31.3%(171/546)、0.6%(3/508)和0.7%(3/416)。结论 本院革兰阴性菌呈增多趋势,尤其广泛耐药的肺炎克雷伯菌应引起高度关注,做好细菌耐药性监测,加强临床抗菌药物的合理使用和医院感染控制。 相似文献
2.
Gut bacteria and gut barrier plays important roles in body homeostasis. Ciprofloxacin (CPFX) is widely used to treat bacterial infections. However, whether high dosage of CPFX has side effects on gut barrier integrity is still unclear. Our results indicated that the High CPFX treatment (1 mg/ml) caused weight loss, nervousness, anorexia, and increased apoptosis cells in gut, but less influence was observed in the Low CPFX group (0.2 mg/ml). Meanwhile, the High CPFX treatment impaired tight junction molecules Ocln/ZO-1 level and down-regulated antibacterial genes expression (reg3γ, pla2g2α and defb1). Further, the High CPFX treatment increased pro-inflammatory cytokine IL-1β in intestinal tract, decreased IL-17A of duodenum but increased IL-17A of colon at day 37. In addition, the gut bacterial diversity and richness behaved significantly loss regarding CPFX treatment, especially in the High CPFX group during the experiment. Indole exhibited sharply decline in both Low and High CPFX groups at day 7, and the High CPFX mice needed longer time on restoring indole level. Meanwhile, CPFX treatment strongly decreased the concentrations of butyric acid and valeric acid at day 1. Correlation analysis indicated that the linked patterns between the key bacteria (families Bacteroidales_S247, Ruminococcaceae and Desulfovibrionaceae) and metabolites (indole and butyric acid) were disturbed via the CPFX treatment. In conclusion, the High CPFX treatment impaired the gut barrier with the evidence of reduced expression of tight junction proteins, increased apoptosis cells and inflammatory cells, decreased the bacterial diversity and composition, which suggesting a proper antibiotic-dosage use should be carefully considered in disease treatment. 相似文献
3.
Olga A. Klein Avril Drummond Jacqueline R. Mhizha-Murira Laura Mansford Roshan dasNair 《Neuropsychological rehabilitation》2019,29(4):491-512
While previous randomised controlled trials and meta-analyses offer only limited evidence for the effectiveness of cognitive rehabilitation, qualitative studies examining patient perspectives report more positive outcomes. This meta-synthesis of qualitative studies examined patient perspectives of cognitive rehabilitation for memory, attention, and executive function problems in people with multiple sclerosis. Using set eligibility criteria, we screened electronic databases, reference lists, and academic networks for relevant papers. Seven papers (195 participants) were selected. Two independent researchers conducted quality appraisals of papers. Data analysis, guided by the thematic synthesis approach, yielded six main themes. These suggested that patients benefitted from the group environment in rehabilitation. Cognitive rehabilitation facilitated the participants’ reflection and awareness of their cognitive deficits, and was associated with increased knowledge and understanding of their illness. Increased strategy use was reported and associated with improvements in cognitive functioning and greater confidence and perseverance. Participants reported emotional and social improvements, and felt more optimistic. Overall, these changes had a positive impact on participants’ quality of life. This synthesis of qualitative studies indicates that people with multiple sclerosis who experience cognitive deficits benefit from cognitive rehabilitation programmes. This finding must, however, be viewed in light of the limitations of this meta-synthesis. The meta-synthesis was registered in the PROSPERO database under CRD42017040148. 相似文献
4.
D. Baker G. Pryce L. K. James K. Schmierer G. Giovannoni 《European journal of neurology》2020,27(2):221-228
Clinical trials are probably the most informative experiments to help an understanding of multiple sclerosis (MS) biology. Recent successes with CD20‐depleting antibodies have focused attention towards B cell subsets as important mediators in MS. The trial of tabalumab (NTC00882999), which inhibits B cell activation factor (BAFF), is reported and reviewed and this trial is contrasted with the trial on the inhibition of a proliferation‐inducing ligand (APRIL) and BAFF using atacicept (NCT00642902). Both tabalumab and atacicept induce depletion of mature B cells and inhibit antibody formation, but they fail to deplete memory B cells and do not inhibit relapsing MS. Atacicept is reported to augment memory B cell responses and may precipitate relapse, suggesting the importance of APRIL. However, BAFF inhibition can enhance peripheral blood memory B cell responses, which was not associated with augmented relapse. Although other interpretations are possible, these data further support the hypothesis that memory B cells may be of central importance in relapsing MS, as they are the major CD20+ B cell subset expressing APRIL receptors. They also suggest that quantitative and/or qualitative differences in B cell responses or other factors, such as an immune‐regulatory effect associated with APRIL, may be important in determining whether MS reactivates following neutralization of peripheral B cell maturation and survival factors. 相似文献
5.
6.
7.
8.
9.
目的通过检查有龋及无龋母亲的口腔卫生状况,并通过随访收集其婴儿1个月(1月龄)及6个月(6月龄)的唾液样本测序分析,观察母亲患龋情况对其婴儿口腔微生物多样性的影响。方法通过筛查收集1月龄婴儿的唾液样本;于首次采样时记录母亲的口腔卫生状况,根据母亲患龋情况将婴儿分为母亲有龋组(简称有龋组)和母亲无龋组(简称无龋组),跟踪随访至婴儿6个月时再次收集唾液样本。通过高通量测序的方法,分析婴儿不同月龄微生物多样性的变化。结果本研究随访受试者10例(男6例,女4例),其中有龋组7例,无龋组3例,各组间的微生物群落多样性Shannon指数均无显著性差异(P>0.05)。无龋组婴儿1月龄至6月龄时微生物群落的物种组成有较大变化;有龋组婴儿在1月龄和6月龄时组内各样本间物种组成均差异较大;1月龄时两组微生物群落较相似,而至6月龄时两组婴儿唾液的物种组成已开始发生变化。结论有龋组婴儿口腔内菌群多样性总体高于无龋组,在1月龄至6月龄间婴儿口腔内微生物物种的多样性及丰度均有了不同程度的提高。 相似文献
10.